Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728779 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Body Radiation With Nelfinavir for Oligometastases
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01728779 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 38 participants.
The verdict
NCT01728779, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
Interventions
- DRUG Nelfinavir
- RADIATION Stereotactic Body Radiation (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-01-08 |
| Est. Completion | 2020-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01728779
The ClinicalTrials.gov registry entry for NCT01728779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nelfinavir is the first listed.
NCT01728779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01728779 about?
NCT01728779 is a clinical study titled "Stereotactic Body Radiation With Nelfinavir for Oligometastases". Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once...
What is the current status of trial NCT01728779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2014-01-08. Estimated completion is 2020-12.
What interventions are being tested in trial NCT01728779?
The interventions under investigation include: Nelfinavir (DRUG), Stereotactic Body Radiation (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01728779?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.